AA
TRML

AlphaCentric Advisors’s Tourmaline Bio TRML Stock Holding History

AlphaCentric Advisors’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,500
Closed -$141K – 279
2024
Q3 		$141K Sell
5,500
-69,500
-93% -$1.16M 0.11% 151
2024
Q2 		$965K Buy
75,000
+13,900
+23% +$224K 0.71% 48
2024
Q1 		$1.4M Buy
+61,100
New +$2.15M 0.84% 45

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

AlphaCentric Advisors's TRML Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Tourmaline Bio (TRML) in Q4 2024, closing a stake of 5,500 shares — an estimated $141K sold.

AlphaCentric Advisors first reported a position in TRML in Q1 2024 and held it in 3 quarters. The position peaked at $1.4M in Q1 2024. 101 funds tracked by Wall St. Rank hold TRML as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Tourmaline Bio position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 5,500 Tourmaline Bio shares in Q4 2024, an estimated $141K.
  • AlphaCentric Advisors first reported a position in Tourmaline Bio in Q1 2024 and held it in 3 quarters.
  • AlphaCentric Advisors's Tourmaline Bio position peaked at $1.4M in Q1 2024.
  • 101 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.